Association of warfarin dose with genes involved in its action and metabolism. - Wikidata - awgldk - TriplyDB

Association of warfarin dose with genes involved in its action and metabolism.

Association of warfarin dose with genes involved in its action and metabolism.

http://www.wikidata.org/entity/Q35633802

about

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences Pharmacogenomics and cardiovascular disease Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians High-dimensional pharmacogenetic prediction of a continuous trait using machine learning techniques with application to warfarin dose prediction in African Americans Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation Estimation of the warfarin dose with clinical and pharmacogenetic data.VKORC1 haplotypes in five East-Asian populations and Indians.Assessing cytochrome P450 and UDP-glucuronosyltransferase contributions to warfarin metabolism in humans.Screening for 392 polymorphisms in 141 pharmacogenes.Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Warfarin therapy: in need of improvement after all these years.Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications.Implementing genotype-guided antithrombotic therapy.Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.Genotype-based dosing algorithms for warfarin therapy: data review and recommendations.A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.Pharmacogenetics of anticoagulants.A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.Pharmacogenetic association study of warfarin safety endpoints in Puerto Ricans Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model.Genetics of warfarin sensitivity in an emergency department population with thromboembolic.Effect of single-dose rifampin on the pharmacokinetics of warfarin in healthy volunteers.Warfarin dosage response related pharmacogenetics in Chinese population.Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing.Interaction between warfarin and Chinese herbal medicines Detection of common single nucleotide polymorphisms synthesizing quantitative trait association of rarer causal variants.Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.Cardiovascular pharmacogenomics Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII

P2860

Q24641999-D98F37ED-34A6-497C-B691-360D9EFE91D8 Q26746062-097C8921-2F59-416B-892A-4C6049F1A120 Q26997380-98005C2B-894C-4328-B0C1-E5097D251613 Q27002899-D7C72D21-B35E-4767-9676-17EF418CC161 Q27006860-035DD4D4-414A-4516-8E9F-FFA2F797C141 Q27011524-5EF02A9F-9B72-4507-9748-7C8EBDDCDAB0 Q28395337-E8034306-C05C-4F9B-AFD6-F8FDD0756BDC Q28475004-94CEC702-CCD7-4409-BB68-1FD83E1F166F Q28483861-EAC2B340-86C3-4B08-A6CB-B393030B705E Q28740452-3F32082E-1F91-46AA-A8AB-68F2C1782192 Q29006772-58928947-A313-4E33-95B4-1ADDD262B83F Q31016306-F90226DC-3936-4182-A1F3-EB91A37D302B Q31042226-49842D00-84BF-4D1D-9F54-46864D1AD5FF Q33410725-873DABC8-00A7-48DC-9784-A5FBAECA26D7 Q33511512-A3922CA4-4B93-4A62-BA3C-75F838BBCD8A Q33644101-B10C8FB7-9C0E-4E28-B0B5-87E2E0AA7A24 Q33733501-A7895FF6-406E-4AB9-AF56-52656D356242 Q33792352-C5329849-F6F7-45F0-89C3-2D8D1A47CBFA Q33793086-D13D8C1D-AFDE-498A-93EF-0B7ECCD1E12F Q33943678-A2E8D477-D658-4F1A-B0AD-4BD84C96934A Q33990428-0A6F568C-B104-42AA-8EE3-54869F3B7B68 Q33990441-183BE8AC-97C8-469A-8714-007EE8E2A05E Q34050936-1293ED33-EF33-43FC-9AD5-C19F7189DE12 Q34065133-F1BF7E7F-3589-4FDF-BB42-6FCB44B4CAED Q34085379-D632D25F-3D81-4FD9-9AB7-30694E186687 Q34219746-B8F424B6-6032-4CF6-A3EE-4F240C90542D Q34273608-17F67C78-8FFE-4615-A29F-6253ECECB2B1 Q34337948-00149228-2811-4440-A8D1-F080030333B8 Q34362277-213C7BEB-F9E0-4BE6-93B6-F008327A06D4 Q34571746-49D3DCA1-D458-490C-BF7E-4E25571F55E1 Q34834319-2174A280-DF59-4E4D-B934-1BC9B4381E76 Q34934523-F6EBE1CB-2A47-4A9B-8422-6AD201068625 Q34969837-C855DBA7-6EE5-4DB4-8D57-EF48C67DFB0C Q34977531-C9BE524F-6CC6-4D52-87D1-8FD4FE5006E1 Q35037456-0E31CD48-40FD-42C4-A0DF-7A62ABE654DB Q35076285-FC9CD4CA-8D84-4D13-A703-6D84293A644C Q35085288-6E4B56CE-F479-49D6-A959-9B36FB5DA79B Q35092508-97D0B0DE-6B71-4E16-9BCE-378812BCF2AA Q35447163-ABAAB951-A492-4615-AEA3-0259DC83E1A0 Q35678294-15AEA37A-2DD4-4381-86F4-CC4D1B62F886

P2860

Association of warfarin dose with genes involved in its action and metabolism.

http://www.wikidata.org/entity/Q35633802

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Association of warfarin dose with genes involved in its action and metabolism.

@ast

Association of warfarin dose with genes involved in its action and metabolism.

@en

type

label

Association of warfarin dose with genes involved in its action and metabolism.

@ast

Association of warfarin dose with genes involved in its action and metabolism.

@en

prefLabel

Association of warfarin dose with genes involved in its action and metabolism.

@ast

Association of warfarin dose with genes involved in its action and metabolism.

@en

P1433

Q35633802-4F5A08D6-469F-4950-A1D4-ECAFDE1177E6

P1476

Q35633802-0D6527D8-CC3F-4ABD-9572-7C6998509077

P2093

Q35633802-047A0778-6F7B-48EA-A205-40D8866339AC

Q35633802-3B537966-DA9F-43AA-9160-6332E8E8E10D

Q35633802-58D6743F-60E8-4A75-8D2F-75A5BB5908E7

Q35633802-67E3D16E-0AFF-45C8-AB26-8FF477996210

Q35633802-91782CCF-C017-46E0-A673-90897EF87E2C

Q35633802-9DFF4C57-7B97-4BB1-93F4-0AB75AB3B10B

Q35633802-B5D1579F-3E96-4DE3-AA97-DD8AA1F1EF31

P2860

Q35633802-01B9C9BC-B170-43CA-A2BA-5AE4F19FA1B1

Q35633802-04FC5FDF-98AE-47F2-BD31-499B730E379B

Q35633802-06272AA7-B474-4E28-922F-7E0AA09102BE

Q35633802-0658AAA7-C654-4410-AEE4-42F25E922C3D

Q35633802-19F61286-D474-4465-8907-AD1FCB298012

Q35633802-2791AF4C-C9B7-4359-B9FF-746E83F8EDC3

Q35633802-2D27DD5D-7B8E-43CB-87F6-46B193F33655

Q35633802-2FFA6A77-29E5-435E-A960-6C63ADA11E7C

Q35633802-3CA4F940-52B8-4AB7-94FA-70B7AF585BB7

Q35633802-470AD290-C117-4E99-A6B4-D4C550D5251F

P2888

Q35633802-1EE6AB5F-7E7F-4FC7-B01E-092A337A03A5

P304

Q35633802-E1559EE1-15CF-4A4B-A590-AD127BF8413C

P31

Q35633802-8B372571-3DDD-402A-A3B4-C248CAF397FC

P356

Q35633802-466D6C1F-9074-4CEA-8F42-E9D1809837B3

P433

Q35633802-93D524B4-FEC0-4327-989A-C185FE6CB6D0

P478

Q35633802-123EFE62-2C4B-44E6-8932-19FF3ED40B0E

P50

Q35633802-2EDED72B-96B6-4E27-98C6-00D77BCC13FC

Q35633802-D5202065-E9B8-490A-84A9-178E53B9B89D

P577

Q35633802-2C357507-55E4-4DCE-971E-6A8F5FB88E3C

P5875

Q35633802-5219E7EF-D429-4B83-B53D-782BFD9C579A

P698

Q35633802-C93C95A4-B2FF-450E-B0D0-6B30B6324C70

P932

Q35633802-B51153CD-D321-4FF7-990F-B5F52972CFB9

P356

S00439-006-0260-8

P1433

P1476

Association of warfarin dose with genes involved in its action and metabolism.

@en

P2093

Claes Wadelius

http://www.w3.org/2001/XMLSchema#string

David Bentley

http://www.w3.org/2001/XMLSchema#string

Jilur Ghori

http://www.w3.org/2001/XMLSchema#string

Leslie Y Chen

http://www.w3.org/2001/XMLSchema#string

Niclas Eriksson

http://www.w3.org/2001/XMLSchema#string

Ralph McGinnis

http://www.w3.org/2001/XMLSchema#string

Suzannah Bumpstead

http://www.w3.org/2001/XMLSchema#string

P2860

The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions

Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients

The structure of haplotype blocks in the human genome

The vitamin K-dependent carboxylase

Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity

Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

Identification of the gene for vitamin K epoxide reductase

Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles

The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats

P2888

s00439-006-0260-8

P304

23-34

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00439-006-0260-8

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

121

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6747741

http://www.w3.org/2001/XMLSchema#string

P698

17048007

http://www.w3.org/2001/XMLSchema#string

P932

1797064

http://www.w3.org/2001/XMLSchema#string